

# Enhancing Molecular Generation with FragGPT-Guided Genetic Algorithms

Tianguai Yao, Zhangfan Yang, Junkai Ji, *Member, IEEE*

**Abstract**—De novo molecular design poses a significant challenge in drug discovery, necessitating a delicate balance between exploring vast chemical spaces and targeting promising regions for optimization. This paper introduces FragGPT-GA, a novel hybrid evolutionary framework that synergistically combines a Genetic Algorithm (GA) with a Generative Pre-trained Transformer (GPT) to address this challenge. The core of our approach lies in using the GA for fine-grained structural optimization, while leveraging a fragment-based GPT model as an intelligent diversity generation operator. Specifically, the GPT model generates novel molecular candidates from masked fragments of the parent population, injecting high-quality and diverse individuals into the evolutionary loop. This mechanism enhances the exploratory capabilities of the GA, effectively preventing premature convergence to local optima. We demonstrate through comprehensive experiments, targeting a specific protein, that FragGPT-GA significantly outperforms traditional GA-only baselines in the generation of molecules with superior docking scores, drug-likeness (QED), and synthetic accessibility (SA). Our framework provides a powerful and robust strategy for efficient molecular discovery and optimization.

**Index Terms**—Evolutionary Computation, Genetic Algorithm, Generative Pre-trained Transformer (GPT), De Novo Drug Design, Molecular Optimization, Hybrid Intelligence.

## I. INTRODUCTION

DE novo drug design, the computational generation of novel molecules with desired pharmacological properties, is a cornerstone of modern pharmaceutical research. The sheer size of the chemical space, estimated to be larger than  $10^{60}$  molecules, makes exhaustive search infeasible. Therefore, intelligent search strategies are paramount.

Evolutionary Algorithms (EAs), particularly Genetic Algorithms (GAs), have been widely applied to molecular optimization tasks. They excel at exploiting promising regions of the chemical space through operators like crossover and mutation. However, GAs often suffer from a loss of population diversity, leading to premature convergence and limiting their ability to discover truly novel molecular scaffolds.

On the other hand, deep generative models, such as Generative Pre-trained Transformers (GPTs), have shown remarkable success in learning the underlying distribution of chemical data and generating diverse and valid molecules. Their strength lies in exploration. However, guiding these models to generate molecules optimized for multiple, specific objectives (e.g.,




Fig. 1. Multi-objective performance comparison across key baseline methods. FragGPT-GA demonstrates superior performance with better balance across all metrics: binding affinity, drug-likeness (QED), synthetic accessibility, and novelty. The radar chart illustrates that FragGPT-GA achieves the best overall performance profile compared to RGA, AutoGrow4.0, and MARS baselines.

high binding affinity and good ADMET properties) remains a significant challenge.

This paper addresses the limitations of both approaches by proposing a tightly-coupled hybrid framework, FragGPT-GA. As illustrated in Fig. 1, our approach achieves superior performance with better balance across multiple objectives, demonstrating the best overall performance profile compared to existing baseline methods. We bridge the gap between exploration and exploitation by integrating a fragment-based GPT directly into the GA's evolutionary cycle. Our main contributions are:

- 1) We propose the FragGPT-GA framework, a novel hybrid algorithm that synergizes a GA's optimization power with a GPT's diversity generation capabilities for molecular design.
- 2) We introduce a unique mechanism where a GPT acts as an intelligent "diversity infusion" operator, generating new candidates from masked molecular fragments of the current population at each generation.
- 3) We conduct extensive experiments demonstrating that FragGPT-GA achieves state-of-the-art performance in generating high-quality molecules compared to baseline methods.

## II. RELATED WORK

De novo molecular design has emerged as a cornerstone of computational drug discovery, with various methodologies

T. Yao, Z. Yang, and J. Ji are with the College of Computer Science and Software Engineering, Shenzhen University, Shenzhen 518060, China (e-mail: 2400671005@mails.szu.edu.cn; yangzhangfan@szu.edu.cn; ji-junkai@szu.edu.cn).

Manuscript received December 15, 2024; revised January 20, 2025.

addressing the challenge of navigating vast chemical spaces to identify molecules with desired pharmacological properties. This section systematically reviews the evolutionary landscape of molecular optimization approaches, categorizing them by their core computational paradigms and analyzing their respective strengths and limitations.

### A. Evolutionary Algorithms in Molecular Optimization

Evolutionary algorithms (EAs) have established themselves as robust optimization frameworks for molecular design, leveraging population-based search strategies to explore chemical space systematically. Traditional genetic algorithms encode molecules using string representations such as SMILES or graph-based structures, evolving populations through selection, crossover, and mutation operators guided by fitness functions derived from docking scores, bioactivity predictions, or multi-objective criteria.

**Classical Genetic Approaches:** Early implementations like Graph-GA [1] operate directly on molecular graph representations, employing specialized crossover and mutation operators designed for graph structures. These methods demonstrate computational efficiency through parameter-free designs but suffer from limited exploration diversity. Similarly, traditional GA frameworks often implement chemically-aware heuristics such as BRICS-guided edits and reaction-based mutations to maintain chemical validity and synthesizability.

**Enhanced Evolutionary Strategies:** More sophisticated approaches integrate neural network guidance to address exploration limitations. The GA+D framework [2] augments genetic optimization with discriminator networks, employing SELFIES molecular representation to guarantee chemical validity while using neural networks to guide the evolutionary process. However, these discriminator-based approaches often require extensive hyperparameter tuning and may introduce computational overhead that limits scalability.

**Limitations of Pure Evolutionary Approaches:** Despite their optimization prowess, vanilla genetic algorithms suffer from fundamental limitations: (1) *diversity collapse* - populations tend to converge prematurely around local optima, reducing scaffold novelty; (2) *mode-seeking behavior* - the selection pressure often drives populations toward similar chemical motifs, limiting exploration of diverse chemotypes; (3) *limited generative capacity* - traditional crossover and mutation operators struggle to introduce genuinely novel structural patterns beyond local modifications of existing molecules.

### B. Deep Generative Models for Molecular Design

The advent of deep learning has revolutionized molecular generation, with various generative modeling paradigms demonstrating remarkable capabilities in learning chemical distributions and sampling novel molecular structures.

**Autoregressive and Variational Models:** Junction Tree Variational Autoencoders (JTVAE) [3] decompose molecules into chemically meaningful substructures, enabling structured generation while maintaining chemical validity. These approaches excel at capturing local chemical patterns but often struggle

with long-range dependencies and complex multi-ring systems.

**Reinforcement Learning Approaches:** REINVENT [4] employs recurrent neural networks for SMILES-based generation through reinforcement learning paradigms, demonstrating the ability to optimize molecules toward specific objectives. However, these methods face challenges in balancing exploration and exploitation, often requiring careful reward engineering and suffering from training instability. More sophisticated approaches like MolDQN [5] formulate molecular design as sequential decision-making processes using Markov Decision Process principles, but they struggle with sample efficiency and may converge to suboptimal solutions.

**Multi-Objective Generation:** Advanced frameworks address multi-objective optimization challenges. RationaleRL [6] implements policy gradient optimization through message-passing neural networks for molecular graph generation, incorporating interpretable substructures. MARS [7] executes Markov Chain Monte Carlo sampling with temperature annealing schemes for multi-objective molecular discovery, utilizing graph neural networks for proposal generation.

**3D-Aware Generation:** Recent developments include 3D structure-aware approaches like Gen3D [8], which generates molecules considering three-dimensional constraints for structure-based drug design. While promising, these methods often require extensive computational resources and may struggle with complex binding pocket geometries.

**Limitations of Pure Generative Approaches:** Despite impressive generative capabilities, deep learning models face significant challenges: (1) *objective steering difficulty* - directing generation toward multi-objective optima (e.g., simultaneous optimization of binding affinity, drug-likeness, and synthetic accessibility) remains non-trivial; (2) *sample inefficiency* - reinforcement learning-based approaches often require extensive sampling to achieve convergence; (3) *training instability* - policy gradient methods and adversarial training can be unstable, leading to mode collapse or poor convergence; (4) *limited exploitation* - purely generative approaches lack the systematic exploitation capabilities of evolutionary algorithms.

### C. Hybrid and Multi-Strategy Approaches

Recognizing the complementary strengths of evolutionary and generative paradigms, recent research has explored hybrid methodologies that combine multiple optimization strategies.

**Loose Coupling Strategies:** Early hybrid approaches typically employ loose coupling mechanisms, such as initializing GA populations with generative models or periodically reseeding populations with neural proposals. While these methods demonstrate some improvement over individual approaches, they often underutilize model priors and may disrupt established GA dynamics.

**Guided Exploration Methods:** GEGL [9] represents a more sophisticated approach, guiding deep molecular optimization with genetic exploration. However, this method faces challenges in maintaining the balance between genetic algorithm rigour and neural network flexibility, often requiring extensive hyperparameter optimization.

**Current Limitations of Hybrid Approaches:** Existing hybrid methodologies suffer from several key limitations: (1) *integration depth* - most approaches implement shallow integration, failing to leverage the full potential of both paradigms; (2) *dynamic balance* - maintaining optimal balance between exploration (generative) and exploitation (evolutionary) components throughout optimization remains challenging; (3) *computational efficiency* - combining multiple complex algorithms often results in significant computational overhead; (4) *objective coordination* - ensuring that both generative and evolutionary components work toward consistent multi-objective goals is non-trivial.

#### D. Fragment-Based Molecular Design

Fragment-based approaches have gained prominence in both traditional medicinal chemistry and computational drug design, leveraging the principle that complex molecules can be decomposed into smaller, chemically meaningful building blocks.

**Traditional Fragment Approaches:** Classical fragment-based drug design relies on identifying small molecular fragments that bind to target proteins, subsequently linking or growing these fragments into larger, more potent compounds. This approach has proven successful in medicinal chemistry but often requires extensive manual intervention and domain expertise.

**Computational Fragment Methods:** Recent computational approaches have attempted to automate fragment-based design, using techniques such as BRICS decomposition to break molecules into chemically sensible fragments. However, these methods often struggle with fragment recombination and may generate chemically implausible structures.

Our FragGPT-GA framework addresses the limitations of existing approaches through several key innovations: (1) *tight integration* - we implement deep integration between fragment-based GPT generation and genetic algorithm optimization, where the GPT operates as an intelligent diversity operator within the GA loop; (2) *dynamic masking* - our approach employs dynamic fragment masking that adapts exploration intensity throughout the optimization process; (3) *multi-objective coordination* - both generative and evolutionary components are coordinated toward consistent multi-objective goals through NSGA-II selection; (4) *chemical validity preservation* - the fragment-based GPT approach ensures high chemical validity while maintaining synthetic accessibility.

### III. THE PROPOSED FRAGGPT-GA

#### A. Framework Overview

FragGPT-GA is a tightly coupled hybrid framework developed to overcome the limitations of conventional GAs and fragment-based generative models. As illustrated in Fig. 2, the framework operates through a multi-stage iterative process in which each generation cycle comprises five interconnected phases: (1) *fragment-based molecular decomposition*, (2) *intelligent GPT-driven diversity generation*, (3) *population-aware genetic operations*, (4) *multi-objective fitness evaluation*, and

(5) *Pareto-optimal selection*. The core innovation is to integrate a fragment-aware GPT directly into the GA’s evolutionary loop, thereby bridging the gap between exploration and exploitation. Within each generation, the GA drives optimization through selection and variation, while the GPT functions as a diversity-oriented operator by generating novel candidate molecules from masked molecular fragments of the current population. This mechanism allows our framework to effectively bridge the gap between exploration and exploitation, leveraging the GA for focused optimization while utilizing the GPT to introduce diverse, high-quality structures, ultimately leading to a more balanced and superior performance profile across multiple objectives.

#### B. Fragment-Based GPT and Dynamic Masking

FragGPT-GA operates by first representing molecules in a fragment-based molecular representation, FragSeq, a fragment-level molecular language derived from the standard SMILES. To construct a FragSeq representation, a molecule is systematically deconstructed into a sequence of fragments following the Bond-Retrosynthesis-In-Combination-Strategy (BRICS) rules. BRICS defines a finite set of chemical environments to select synthetically plausible cleavage sites and to retain attachment labels, ensuring that the resulting fragments are chemically valid and stitchable. This decomposition process transforms a non-sequential graph structure into an ordered sequence of fragments, processed from left to right. An illustrative example of this conversion from a SMILES string to its corresponding FragSeq is provided in Fig. 2. This sequential format is particularly advantageous as it allows a language model to naturally capture the contextual and syntactical relationships between constituent fragments within a molecule.

The FRAGPT model is a generative pre-trained transformer designed to operate on the FragSeq representation. It learns the underlying chemical rules and statistical distribution of molecular structures from a large dataset. The model functions autoregressively, generating a new molecule fragment by fragment. Given a sequence of preceding fragments, FRAGPT predicts the probability distribution for the next fragment, thereby extending the molecular structure sequentially. This generative process for a molecule  $m$ , composed of a sequence of  $L$  fragments  $(f_1, f_2, \dots, f_L)$  can be formally expressed as the product of conditional probabilities:

$$p_{\theta}(m) = \prod_{t=1}^T p_{\theta}(f_i | f_{<i}), \quad (1)$$

where  $f_i$  is the  $i$ -th fragment,  $f_{<i}$  represents the sequence of all preceding fragments  $(f_1, \dots, f_{i-1})$ . By sampling from these learned distributions, FRAGPT can assemble novel molecules that adhere to valid chemical principles. In our framework, FRAGPT is utilized to generate a new population of molecules based on the existing population from the genetic algorithm, serving as a sophisticated and chemically aware operator for generating offspring.

Another key point in FRAGPT-GA is the introduction of a dynamic masking mechanism to adaptively control the




Fig. 2. The iterative workflow of the proposed FragGPT-GA framework. The process synergizes a Genetic Algorithm (GA) for optimization with a Generative Pre-trained Transformer (GPT) for diversity expansion, featuring dynamic fragment masking and multi-objective selection.

influence of the FRAGPT model throughout the evolutionary process. This mechanism governs the degree of structural modification by determining the number of fragments to be masked (and subsequently regenerated by FRAGPT) in a given molecule. This relationship is defined by the following equation:

$$n_{mask}(g) = n_{initial} + \frac{g - 1}{G_{max} - 1} \cdot (n_{final} - n_{initial}) \quad (2)$$

where  $g$  represents the current generation,  $G_{max}$  is the maximum number of generations,  $n_{initial}$  is the number of fragments masked in the first generation, and  $n_{final}$  is the number of fragments masked in the final generation. This strategy establishes a clear schedule for the algorithm’s behavior. In the early stages of evolution (when  $g$  is small), the masking ratio is high ( $n_{mask}(g) \approx n_{initial}$ ). This encourages FRAGPT to generate substantially new molecular scaffolds by replacing large portions of the parent molecules, promoting broad **exploration** of the chemical space. As the algorithm progresses towards later generations (as  $g \rightarrow G_{max}$ ), the masking ratio decreases ( $n_{mask}(g) \rightarrow n_{final}$ ). Consequently, FRAGPT performs more localized and subtle modifications, fine-tuning the existing molecular structures to optimize their properties. This later phase emphasizes **exploitation**, refining promising candidates rather than making radical changes. This adaptive approach allows FRAGPT-GA to effectively balance the discovery of novel structures with the optimization of existing ones.

### C. Population-Aware Genetic Operations

Following GPT-based diversity generation, the framework performs sophisticated genetic operations on an expanded population pool  $P_{expanded} = P_g \cup P_{GPT}$ , where  $P_{GPT}$  represents the set of GPT-generated molecules. This expanded pool serves as the input for both crossover and mutation operations, enabling the genetic operators to work with a more diverse and potentially higher-quality substrate.

**Enhanced Crossover Operations:** Our crossover mechanism employs a fragment-aware approach that preserves chemically meaningful substructures while enabling recombination of beneficial motifs from different molecules. The process

operates at the fragment level, ensuring that the resulting offspring maintain chemical validity and synthetic feasibility. **Chemical-Context Mutation:** The mutation operator incorporates chemical knowledge to perform context-appropriate modifications. Rather than random SMILES string manipulations, mutations are guided by chemical rules and synthetic feasibility constraints, increasing the likelihood of generating viable compounds.

### D. Multi-Objective Fitness Evaluation and Optimization

The framework employs a comprehensive multi-objective fitness function that simultaneously optimizes three critical pharmaceutical properties:

$$F(m) = [DS(m), QED(m), SA(m)] \quad (3)$$

where  $DS(m)$  represents the docking score (to be minimized),  $QED(m)$  quantifies drug-likeness (to be maximized), and  $SA(m)$  measures synthetic accessibility (to be minimized). This multi-objective formulation ensures that optimization does not sacrifice drug-like properties or synthetic feasibility in pursuit of binding affinity alone.

The docking evaluation employs AutoDock Vina with standardized protocols, utilizing grid-based molecular docking to assess binding affinity against target proteins. The QED (Quantitative Estimate of Drug-likeness) incorporates multiple pharmaceutical properties including molecular weight, lipophilicity, and topological polar surface area. The SA score estimates synthetic accessibility based on fragment contributions and structural complexity.

### E. Pareto-Optimal Selection via NSGA-II

Selection operates under the NSGA-II (Non-dominated Sorting Genetic Algorithm II) framework, which maintains population diversity while driving convergence toward the Pareto-optimal front. The algorithm performs non-dominated sorting to identify solution fronts, followed by crowding distance calculation to preserve diversity within each front.

The selection process ensures that the framework maintains a balanced portfolio of solutions representing different trade-offs between the three objectives. This approach prevents the

**Algorithm 1** FragGPT-GA Complete Framework

---

**Input:** Initial population  $P_0$ , max generations  $G_{max}$ , GPT model  $\theta$   
**Output:** Pareto-optimal population  $P^*$   
Initialize population  $P_0$  and evaluate  $F(P_0)$   
**for**  $g = 1$  to  $G_{max}$  **do**  
    // Fragment-based decomposition and masking  
     $n_{mask} \leftarrow \text{CalculateDynamicMask}(g, G_{max})$   
     $M_g \leftarrow \text{DecomposeAndMask}(P_{g-1}, n_{mask})$   
    // GPT-powered diversity generation  
     $P_{GPT} \leftarrow \text{GPTGenerate}(M_g, \theta)$   
    // Population-aware genetic operations  
     $P_{pool} \leftarrow P_{g-1} \cup P_{GPT}$   
     $C_{cross} \leftarrow \text{FragmentAwareCrossover}(P_{pool})$   
     $C_{mut} \leftarrow \text{ChemicalContextMutation}(P_{pool})$   
     $C_g \leftarrow \text{ChemicalFilter}(C_{cross} \cup C_{mut})$   
    // Multi-objective evaluation  
    Evaluate  $F(C_g) = [DS(C_g), QED(C_g), SA(C_g)]$   
    // Pareto-optimal selection  
     $P_g \leftarrow \text{NSGA-II-Select}(P_{g-1} \cup C_g)$   
**end for**  
**return** Non-dominated solutions from  $P_{G_{max}}$

---

optimization from converging to a single-objective optimum and provides medicinal chemists with diverse options for further development.

*F. Algorithmic Implementation and Computational Efficiency*

The complete FragGPT-GA algorithm is presented in Algorithm 1. The implementation features several efficiency optimizations: (1) *parallel evaluation* of molecular properties using multiprocessing, (2) *incremental learning* where the GPT model can optionally be fine-tuned on successful molecules from previous generations, and (3) *adaptive resource allocation* that dynamically adjusts computational resources based on population convergence metrics.

The modular architecture facilitates reproducibility and enables systematic ablation studies. Each component—fragment decomposition, GPT generation, genetic operations, evaluation, and selection—operates as an independent module with well-defined interfaces, allowing for easy customization and extension of the framework.

## IV. EXPERIMENTAL SETUP

*A. Datasets and Docking Protocol*

In our experiments, we utilized the ZINC database, a large-scale repository of chemical compounds. Following the procedure in AutoGrow, the molecules were stratified into four groups according to their molecular weights: <100, 100–150, 150–200, and 200–250 Da. FRAGPT-GA then randomly sampled 250 molecules from these groups in the ratio of 2:3:4:1, respectively. To ensure fair comparison with other baselines, we selected the same set of 10 disease-related protein targets, including G-protein-coupled receptors (GPCRs) and kinases from the DUD-E benchmark, as well as the SARS-CoV-2 main protease. For all baseline methods, molecular structures were

processed with MGLTools and subsequently docked using AutoDock Vina. The resulting Vina scores were employed to evaluate the quality of the generated molecules.

*B. Evaluation Metrics*

Our model’s performance was evaluated based on the following metrics, which assess both the overall quality of the generated set and the properties of individual molecules:

- 1) **Novelty:** To evaluate the generative capacity of the model, we compute the novelty score, defined as the fraction of generated molecules not present in the initial population or training set. A higher novelty value reflects the model’s ability to explore novel regions of chemical space beyond memorization.
- 2) **Diversity:** The chemical diversity of the generated molecules is assessed by calculating the average pair-wise Tanimoto distance between their 2048-bit Morgan fingerprints. This measure quantifies structural dissimilarity across the generated set, ensuring that the model does not collapse toward limited structural motifs but instead produces a broad range of compounds.
- 3) **Drug-likeness and Synthetic Accessibility:** Each generated molecule is further evaluated for its pharmaceutical potential. The Quantitative Estimate of Drug-likeness (QED), ranging from 0 to 1, is used to quantify how closely a compound aligns with typical drug-like properties. In parallel, the Synthetic Accessibility (SA) score, ranging from 1 (easily synthesizable) to 10 (difficult to synthesize), estimates the feasibility of practical synthesis based on fragment contributions and structural complexity. Both QED and SA are computed using the RDKit toolkit.
- 4) **Docking Score:** To assess binding affinity to protein targets, we use the AutoDock Vina docking score (Vina score) as an evaluation metric. Lower Vina scores indicate stronger predicted binding interactions and are therefore more desirable. This score provides a direct link between generative outcomes and biological relevance.

## V. RESULTS AND DISCUSSION

*A. Performance Comparison*

To rigorously evaluate the performance of our proposed method, we conducted a comparative analysis against a comprehensive set of baseline algorithms spanning several major paradigms in molecular optimization. The selected methods include: the search-based algorithm screen; generative model-based approaches such as JT-VAE and GEN3D; genetic algorithms including GA+D, Graph-GA, and AutoGrow 4.0; reinforcement learning strategies like MolDQN, RationaleRL, REINVENT, and GEGL; and the Markov Chain Monte Carlo method, MARS. To ensure a fair and direct comparison of optimization efficiency, each method was strictly limited to a budget of 1000 scoring function evaluations. The performance of each algorithm was quantified by the average docking score of the top-1, top-10, and top-100 unique molecules generated during the optimization process.

TABLE I  
DOCKING SCORE COMPARISON (KCAL/MOL, ↓ BETTER)

Method	TOP-100↓	TOP-10↓	TOP-1↓
screening	-9.351±0.643	-10.433±0.563	-11.400±0.630
MARS	-7.758±0.612	-8.875±0.711	-9.257±0.791
MolDQN	-6.287±0.396	-7.043±0.487	-7.501±0.402
GEGL	-9.064±0.920	-9.910±0.990	-10.450±1.040
REINVENT	-10.181±0.441	-11.234±0.632	-12.010±0.833
RationaleRL	-9.233±0.920	-10.834±0.856	-11.642±1.102
JTVAE	-9.291±0.702	-10.242±0.839	-10.963±1.133
Gen3D	-8.686±0.450	-9.285±0.584	-9.832±0.324
GA+D	-7.487±0.757	-8.305±0.803	-8.760±0.796
Graph-GA	-10.848±0.860	-11.702±0.930	-12.302±1.010
Autogrow 4.0	-11.371±0.398	-12.213±0.623	-12.474±0.839
RGA	-11.867±0.170	-12.564±0.287	-12.869±0.473
<b>FragGPT-GA</b>	<b>-12.635±0.090</b>	<b>-13.241±0.190</b>	<b>-13.458±0.442</b>

TABLE II  
DIVERSITY AND DRUG-LIKENESS METRICS (↑ BETTER EXCEPT SA ↓ BETTER)

Method	Nov↑	Div↑	QED↑	SA↓
screening	0%	0.858±0.005	0.678±0.022	2.689±0.077
MARS	100%	<b>0.877±0.001</b>	0.709±0.008	2.450±0.034
MolDQN	100%	<b>0.877±0.009</b>	0.170±0.024	5.833±0.182
GEGL	100%	0.853±0.003	0.643±0.014	2.990±0.054
REINVENT	100%	0.857±0.011	0.445±0.058	2.596±0.116
RationaleRL	100%	0.717±0.025	0.315±0.023	2.919±0.126
JTVAE	98%	0.867±0.001	0.593±0.035	3.222±0.136
Gen3D	100%	0.870±0.006	0.701±0.016	3.450±0.120
GA+D	99%	0.834±0.035	0.405±0.024	5.024±0.164
Graph-GA	100%	0.811±0.037	0.456±0.067	3.503±0.367
Autogrow 4.0	100%	0.852±0.011	0.748±0.022	2.497±0.049
RGA	100%	0.857±0.020	0.742±0.036	2.473±0.048
<b>FragGPT-GA</b>	100%	0.845±0.024	<b>0.764±0.012</b>	<b>2.014±0.153</b>

Table I clearly demonstrate that FragGPT-GA achieves superior docking performance compared to all baseline methods across different evaluation settings (top-1, top-10, and top-100). We attribute this superior performance to the synergistic architecture of FragGPT-GA, which effectively integrates the creative generative power of a molecular language model with the directional pressure of an evolutionary algorithm. Unlike methods that rely on a single strategy, our framework leverages the GPT component for broad exploration, enabling it to propose novel and chemically diverse molecular scaffolds. Simultaneously, the genetic algorithm drives exploitation, efficiently refining promising candidates to optimize their properties. The dynamic masking schedule is crucial in balancing these two forces. In contrast, while other GA-based methods also performed strongly, their conventional operators tend to overexploit recurring motifs and struggle to escape local optima. Similarly, reinforcement learning approaches showed potential but did not reach the same level of performance, possibly due to challenges in stable convergence within a limited budget.

We further assess FragGPT-GA’s multi-objective optimization by evaluating all methods on QED and SA. To verify that improvements are not achieved by sacrificing variety, we also measured the novelty and diversity of the generated molecules.

Table II shows that FragGPT-GA provides the most balanced and overall strongest performance across these dimensions. In terms of diversity, some baselines appear marginally higher but typically trade this for poorer molecular quality, where FragGPT-GA sustains high structural variety without mode collapse or over-concentration on a single scaffold. Notably, FragGPT-GA outperforms all baseline models on QED and SA, the two metrics most critical for practical applicability, by simultaneously enhancing drug-likeness and reducing synthetic complexity. This avoids the common imbalance observed in generative and reinforcement-learning approaches, where improvements in one property often degrade the other.

### B. Generalization Across Multiple Protein Targets

In this experiment, we evaluate the generalizability and robustness of our approach on 10 distinct protein targets and compare it with two strong baselines. The distributions of docking scores for molecules generated for each target are shown as violin plots in Fig. 3.

The results demonstrate that the baseline methods consistently generate molecules with less favorable docking scores. While the baselines show some optimization capability, their upper performance bound appears lower than that of our framework. In contrast, FragGPT-GA significantly outperforms the baselines across all tested protein targets. As illustrated by the violin plots, the distribution of docking scores for molecules generated by our method shifts toward more favorable values, reflecting lower predicted binding energies. This indicates that FragGPT-GA not only discovers high-scoring candidate molecules but also maintains better average docking scores across the generated population. This consistent superiority across diverse targets highlights the robustness of FragGPT-GA and its ability effectively navigate distinct chemical spaces for targeted molecular design.

### C. Ablation Studies

1) *Selection Strategy Comparison:* To evaluate the impact of different selection strategies in our FragGPT-GA framework, we conduct ablation studies comparing three approaches: single-objective selection, multi-objective selection (NSGA-II), and our novel comprehensive scoring function  $S(m)$ .

For single-objective selection, we optimize only the docking score:

$$S_{\text{single}}(m) = -\text{DockingScore}(m) \quad (4)$$

For multi-objective selection, we employ NSGA-II with three objectives:

$$S_{\text{multi-obj}}(m) = \begin{bmatrix} -\text{DockingScore}(m) \\ \text{QED}(m) \\ -\text{SA}(m) \end{bmatrix} \quad (5)$$

Our comprehensive scoring function follows the target property formulation used in previous works, integrating all objectives as a multiplicative composite score:

$$S_{\text{comp}}(m) = \widehat{DS}(m) \times \text{QED}(m) \times \widehat{SA}(m) \in [0, 1] \quad (6)$$






Fig. 3. Protein-specific docking score comparison across three models. Each subplot represents one protein target, with three violin plots showing the distribution of docking scores for AutoGrow4.0 (green/Auto), RGA (pink), and FragGPT-GA (blue/Ours). The violin plots display both population density and individual data points with statistical overlays (red lines: means, blue lines: medians). The top-right corner of each subplot shows the best docking score (TOP1) achieved by each model for that specific protein target. FragGPT-GA consistently demonstrates superior performance across most protein targets, achieving the best TOP1 scores while maintaining population diversity.

where the normalized docking score and synthetic accessibility are computed as:

$$\widehat{DS}(m) = -\frac{\text{clip}(\text{DockingScore}(m))}{20} \in [0, 1] \quad (7)$$

$$\widehat{SA}(m) = \frac{10 - \text{SA}(m)}{9} \in [0, 1] \quad (8)$$

Here,  $\text{clip}(\cdot)$  constrains the docking score to the range  $[-20, 0]$  for normalization. This multiplicative formulation ensures that molecules must achieve reasonable performance across all three dimensions (binding affinity, drug-likeness, and synthetic feasibility) to obtain high composite scores.

Table III presents the performance comparison across different metrics.

The results reveal distinct trade-offs among the three strategies. Single-objective selection achieves competitive docking scores but suffers from poor drug-likeness metrics, with  $S(\text{QED}) = 0.436$  and  $S(\text{SA}) = 3.145$ , confirming the limitation of focusing solely on binding affinity. Multi-objective selection using NSGA-II demonstrates the most balanced performance, achieving strong docking scores while maintaining excellent drug-likeness scores ( $S(\text{QED}) = 0.764$ ,  $S(\text{SA}) =$

TABLE III  
ABLATION STUDY: SELECTION STRATEGY COMPARISON

Metric	Single	Multi-obj	Comp Score
TOP-100↓	-12.014±0.168	-12.635±0.090	-12.301±0.260
TOP-10↓	-13.120±0.020	-13.241±0.190	-13.200±0.310
TOP-1↓	-13.253±0.130	-13.458±0.442	-13.314±0.512
QED↑	0.436±0.034	0.764±0.012	0.579±0.015
SA↓	3.145±0.153	2.014±0.015	2.645±0.176

2.014). Our comprehensive scoring function provides an intermediate solution with moderate performance across all metrics ( $S(\text{TOP-1}) = -13.314$ ,  $S(\text{QED}) = 0.579$ ,  $S(\text{SA}) = 2.645$ ).

2) *Component Contribution Analysis*: To quantify the contribution of each module, we consider the following ablations: (i) *No-GPT*: remove the GPT diversity operator while keeping GA, docking, and NSGA-II unchanged; (ii) *Static-Mask*: replace dynamic masking with a fixed number of masked fragments per generation; (iii) *Single-Objective*: use single-objective selection (docking only) instead of NSGA-II; (iv) *No-Filter*: disable medicinal chemistry filters. We evaluate each ablation under identical initialization and dock-




Fig. 4. Per-target iterative optimization of docking scores across generations for AutoGrow4.0 (green/Auto) and FragGPT-GA (blue/Ours). Each subplot corresponds to one protein target. The y-axis shows the best docking score (lower is better) achieved in each generation, illustrating the optimization dynamics and convergence behavior of both methods.

ing protocols. We observe that removing GPT substantially reduces scaffold novelty and slows improvement in docking; disabling dynamic masking degrades late-stage refinement; single-objective selection yields strong docking but worse QED/SA, indicating overoptimization; removing filters increases invalid or impractical proposals. Overall, the full model strikes the best balance. Fig. ?? illustrates representative convergence trajectories.

#### D. Case Study of Generated Molecules

We inspect top-ranking molecules to understand how FragGPT-GA discovers binding-competent yet drug-like candidates. Qualitatively, GPT proposals introduce distinct scaffolds with substituent patterns that GA later refines toward pocket-complementary shapes. Docking poses reveal recurrent interactions (e.g., hydrogen bonds to conserved residues and hydrophobic packing within the binding cavity). Compared to GA-only baselines, our candidates exhibit improved synthetic accessibility and higher QED at similar docking scores, suggesting that GPT-driven exploration avoids brittle chemotypes. Diversity metrics further indicate broader chemotype coverage without sacrificing validity. Representative molecules and binding mode depictions are provided in the supplementary figures.

## VI. CONCLUSION

This work addresses a fundamental challenge in computational drug discovery: the design of effective molecular optimization algorithms that can simultaneously balance exploration and exploitation while maintaining chemical validity and multi-objective performance. Traditional genetic algorithms, despite their optimization prowess, suffer from critical limitations including diversity collapse, premature convergence to local optima, and limited capacity for scaffold hopping. Conversely, deep generative models, while exhibiting remarkable generative capabilities, struggle with objective steering and systematic exploitation of promising chemical regions.

Our proposed FragGPT-GA framework successfully resolves these limitations through several key innovations. First, we establish a tightly integrated hybrid architecture where a fragment-based GPT model functions as an intelligent diversity operator within the genetic algorithm loop, rather than employing loose coupling strategies prevalent in existing hybrid approaches. This integration enables the system to leverage the learned chemical knowledge of large language models while maintaining the systematic optimization capabilities of evolutionary algorithms. Second, our dynamic masking strategy adaptively balances exploration intensity throughout



the optimization process, enabling broad scaffold exploration in early generations while promoting targeted refinement in later stages. Third, the multi-objective optimization framework using NSGA-II ensures that improvements in binding affinity do not compromise drug-likeness or synthetic accessibility.

Experimental validation across multiple protein targets demonstrates that FragGPT-GA achieves superior performance compared to established baselines, including state-of-the-art methods such as RGA, AutoGrow4.0, MARS, and various deep learning approaches. Our method consistently generates molecules with better docking scores (TOP-1:  $-13.458 \pm 0.442$  kcal/mol), enhanced drug-likeness (QED:  $0.764 \pm 0.012$ ), and improved synthetic accessibility (SA:  $2.014 \pm 0.153$ ) while maintaining 100% novelty. The comprehensive protein-specific analysis across 10 diverse targets further confirms the robustness and generalizability of our approach.

Despite these achievements, several limitations warrant acknowledgment and future investigation. **First, computational complexity:** The integration of GPT inference within each evolutionary generation introduces significant computational overhead compared to traditional genetic algorithms. While this cost is justified by the quality improvements, developing more efficient inference strategies or model compression techniques could enhance practical applicability. **Second, objective function limitations:** Our current framework focuses on three primary objectives (binding affinity, drug-likeness, and synthetic accessibility). However, comprehensive drug discovery requires consideration of additional ADMET properties, toxicity profiles, and selectivity constraints, necessitating expansion of the objective space. **Third, generalization constraints:** Although we demonstrate effectiveness across multiple protein targets, the fragment-based GPT model's performance is inherently limited by its training data distribution. Transfer to protein families or chemical spaces significantly different from the training corpus may require domain adaptation strategies. **Fourth, evaluation metric dependencies:** Our assessment relies primarily on computational predictions (docking scores, QED, SA scores), which, while well-established, may not fully capture the complexity of actual biological systems and synthetic chemistry challenges.

**Fifth, scalability considerations:** The current framework requires careful hyperparameter tuning for optimal performance across different targets, potentially limiting its plug-and-play applicability. Developing adaptive parameter selection mechanisms could enhance usability. **Sixth, chemical space coverage:** While our method demonstrates excellent scaffold hopping capabilities, the exploration is still constrained by the GPT model's learned representations, potentially missing entirely novel chemical motifs not represented in the training data.

Future research directions should address these limitations through several avenues: (1) investigating more efficient neural architectures and inference strategies to reduce computational costs; (2) expanding the objective framework to include comprehensive ADMET and toxicity predictions; (3) developing domain adaptation techniques for improved generalization across diverse protein families and chemical spaces; (4) integrating experimental validation loops to refine computational

predictions; (5) exploring meta-learning approaches for automatic hyperparameter optimization; and (6) investigating techniques for expanding chemical space coverage beyond training data limitations.

In conclusion, FragGPT-GA represents a significant advancement in hybrid evolutionary-generative approaches for molecular optimization, successfully addressing core limitations of existing methodologies while achieving state-of-the-art performance across multiple evaluation metrics. The framework provides a robust foundation for future developments in AI-driven drug discovery, offering both immediate practical value and promising research directions for the community.

## APPENDIX

### PROOF OF THE ZONKLAR EQUATIONS

Use \appendix if you have a single appendix.

### ACKNOWLEDGMENT

The authors would like to thank...

### REFERENCES

- [1] J. H. Jensen, "A graph-based genetic algorithm and generative model/monte carlo tree search for the exploration of chemical space," vol. 10, no. 12, pp. 3567–3572.
- [2] A. Nigam, P. Friederich, M. Krenn, and A. Aspuru-Guzik, "Augmenting genetic algorithms with deep neural networks for exploring the chemical space."
- [3] W. Jin, R. Barzilay, and T. Jaakkola, "Junction tree variational autoencoder for molecular graph generation," pp. 2323–2332.
- [4] M. Olivecrona, T. Blaschke, O. Engkvist, and H. Chen, "Molecular de-novo design through deep reinforcement learning," vol. 9, no. 1, p. 48.
- [5] Z. Zhou, S. Kearnes, L. Li, R. N. Zare, and P. Riley, "Optimization of molecules via deep reinforcement learning," vol. 9, no. 1, p. 10752.
- [6] W. Jin, R. Barzilay, and T. Jaakkola, "Multi-objective molecule generation using interpretable substructures," pp. 4849–4859.
- [7] Y. Xie, C. Shi, H. Zhou, Y. Yang, W. Zhang, Y. Yu, and L. Li, "Mars: Markov molecular sampling for multi-objective drug discovery."
- [8] S. Luo, J. Guan, J. Ma, and J. Peng, "A 3d generative model for structure-based drug design," vol. 34, pp. 6229–6239.
- [9] S. Ahn, J. Kim, H. Lee, and J. Shin, "Guiding deep molecular optimization with genetic exploration," vol. 33, pp. 12008–12021.
- [10] T. Fu, W. Gao, C. W. Coley, and J. Sun, "Reinforced Genetic Algorithm for Structure-based Drug Design," pp. 6759–6778.
- [11] T. Sterling and J. J. Irwin, "Zinc 15 – ligand discovery for everyone," vol. 55, no. 11, pp. 2324–2337.
- [12] S. Lee, K. Kreis, S. P. Veccham, M. Liu, D. Reidenbach, S. Paliwal, A. Vahdat, and W. Nie, "Molecule Generation with Fragment Retrieval Augmentation."
- [13] J. O. Spiegel and J. D. Durrant, "AutoGrow4: An open-source genetic algorithm for de novo drug design and lead optimization," vol. 12, no. 1, p. 25. [Online]. Available: <https://jcheminf.biomedcentral.com/articles/10.1186/s13321-020-00429-4>
- [14] M. Abdelsayed, "AI-Driven Polypharmacology in Small-Molecule Drug Discovery," vol. 26, no. 14, p. 6996. [Online]. Available: <https://www.mdpi.com/1422-0067/26/14/6996>
- [15] C. Ai, H. Yang, X. Liu, R. Dong, Y. Ding, and F. Guo, "MTMol-GPT: De novo multi-target molecular generation with transformer-based generative adversarial imitation learning," vol. 20, no. 6, p. e1012229. [Online]. Available: <https://dx.plos.org/10.1371/journal.pcbi.1012229>
- [16] A. Cerveira, F. Kremer, D. d. A. Lourenço, and U. B. Corrêa, "Evaluation Framework for AI-driven Molecular Design of Multi-target Drugs: Brain Diseases as a Case Study. [Online]. Available: <http://arxiv.org/abs/2408.10482>
- [17] V. A. Cicirello, "Evolutionary Computation: Theories, Techniques, and Applications," vol. 14, no. 6, p. 2542. [Online]. Available: <https://www.mdpi.com/2076-3417/14/6/2542>
- [18] K. Deb, A. Pratap, S. Agarwal, and T. Meyarivan, "A fast and elitist multiobjective genetic algorithm: NSGA-II," vol. 6, no. 2, pp. 182–197. [Online]. Available: <http://ieeexplore.ieee.org/document/996017/>

- [19] Z. Fang, X. Wang, Y. Sun, and M. A. Adibhashimi, "Accelerating multi-objective optimization of concrete thin shell structures using graph-constrained GANs and NSGA-II," vol. 15, no. 1, p. 16090. [Online]. Available: <https://www.nature.com/articles/s41598-025-00017-2>
- [20] B. Huang, R. Cheng, Z. Li, Y. Jin, and K. C. Tan. EvoX: A Distributed GPU-accelerated Framework for Scalable Evolutionary Computation. [Online]. Available: <http://arxiv.org/abs/2301.12457>
- [21] A. Kadan, K. Ryczko, E. Lloyd, A. Roitberg, and T. Yamazaki, "Guided multi-objective generative AI to enhance structure-based drug design," vol. 16, no. 29, pp. 13 196–13 210. [Online]. Available: <https://xlink.rsc.org/?DOI=D5SC01778E>
- [22] T. Khater, S. A. Alkhatib, A. AlShehhi, C. Pitsalidis, A. M. Pappa, S. T. Ngo, V. Chan, and V. K. Truong, "Generative artificial intelligence based models optimization towards molecule design enhancement," vol. 17, no. 1, p. 116. [Online]. Available: <https://jcheminf.biomedcentral.com/articles/10.1186/s13321-025-01059-4>
- [23] J. Meyers and N. Brown. FragGT: Fragment-based evolutionary molecule generation with gene types. [Online]. Available: <https://chemrxiv.org/engage/chemrxiv/article-details/65cf28f266c1381729c70206>
- [24] Qingfu Zhang and Hui Li, "MOEA/D: A Multiobjective Evolutionary Algorithm Based on Decomposition," vol. 11, no. 6, pp. 712–731. [Online]. Available: <http://ieeexplore.ieee.org/document/4358754/>
- [25] Y. Tian, T. Zhang, J. Xiao, X. Zhang, and Y. Jin, "A Coevolutionary Framework for Constrained Multiobjective Optimization Problems," vol. 25, no. 1, pp. 102–116. [Online]. Available: <https://ieeexplore.ieee.org/document/9122020/>
- [26] T. V. T. Tran and T. S. Hy, "Protein Design by Directed Evolution Guided by Large Language Models."
- [27] Z. Wang, K. Zhang, Z. Zhao, Y. Wen, A. Pandey, H. Liu, and K. Ding. A Survey of Large Language Models for Text-Guided Molecular Discovery: From Molecule Generation to Optimization. [Online]. Available: <http://arxiv.org/abs/2505.16094>
- [28] C. Wang, J. Zhao, L. Jiao, L. Li, F. Liu, and S. Yang. When Large Language Models Meet Evolutionary Algorithms: Potential Enhancements and Challenges. [Online]. Available: <http://arxiv.org/abs/2401.10510>
- [29] X. Wu, S.-h. Wu, J. Wu, L. Feng, and K. C. Tan. Evolutionary Computation in the Era of Large Language Model: Survey and Roadmap. [Online]. Available: <http://arxiv.org/abs/2401.10034>
- [30] X. Xia, Y. Zhang, X. Zeng, X. Zhang, C. Zheng, and Y. Su, "CMOMO: A deep multi-objective optimization framework for constrained molecular multi-property optimization," vol. 26, no. 4, p. bbaf335. [Online]. Available: <https://academic.oup.com/bib/article/doi/10.1093/bib/bbaf335/8195924>
- [31] X. Xia, Y. Liu, C. Zheng, X. Zhang, Q. Wu, X. Gao, X. Zeng, and Y. Su, "Evolutionary Multiobjective Molecule Optimization in an Implicit Chemical Space," vol. 64, no. 13, pp. 5161–5174. [Online]. Available: <https://pubs.acs.org/doi/10.1021/acs.jcim.4c00031>
- [32] J. Yoo, W. Jang, and W.-H. Shin, "From part to whole: AI-driven progress in fragment-based drug discovery," vol. 91, p. 102995. [Online]. Available: <https://linkinghub.elsevier.com/retrieve/pii/S0959440X25000132>
- [33] T. Zhang, X. Guo, Y. Li, N. Li, R. Zheng, W. Dong, and W. Ding, "A Dual-Stage and Dual-Population Algorithm Based on Chemical Reaction Optimization for Constrained Multi-Objective Optimization," vol. 13, no. 8, p. 2484. [Online]. Available: <https://www.mdpi.com/2227-9717/13/8/2484>